Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bimagrumab

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Eli Lilly · Phase 2 · Completed · Enrollment 507

NCT05616013

ArmPopulationDoseWeeksEstimandWeight change
Placebo/30 mg/kg BimagrumabObesity or overweight30 mg4n/rn/r
10/30 mg/kg BimagrumabObesity or overweight30 mg4n/rn/r
30 mg/kg BimagrumabObesity or overweight30 mg4n/rn/r
Placebo + 1.0 mg SemaglutideObesity or overweight1.0 mg4n/rn/r
Placebo + 2.4 mg SemaglutideObesity or overweight2.4 mg4n/rn/r
10 mg/kg Bimagrumab + 1.0 mg SemaglutideObesity or overweight1.0 mg4n/rn/r
10 mg/kg Bimagrumab + 2.4 mg SemaglutideObesity or overweight2.4 mg4n/rn/r
30 mg/kg Bimagrumab + 1.0 mg SemaglutideObesity or overweight1.0 mg4n/rn/r
30 mg/kg Bimagrumab + 2.4 mg SemaglutideObesity or overweight2.4 mg4n/rn/r